vs
Healthpeak Properties（DOC）与如新（NUS）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是如新的1.9倍（$719.4M vs $370.3M），Healthpeak Properties净利率更高（73.2% vs 3.9%，领先69.3%），Healthpeak Properties同比增速更快（3.1% vs -16.9%），Healthpeak Properties自由现金流更多（$357.0M vs $5.9M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs -5.8%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
如新企业集团是一家美国多层次直销企业，主打研发并销售个人护理产品与营养膳食补充产品，旗下拥有Nu Skin及Pharmanex两大品牌，目前已在全球54个市场开展业务，依托约120万独立销售代表的销售网络覆盖全球市场。
DOC vs NUS — 直观对比
营收规模更大
DOC
是对方的1.9倍
$370.3M
营收增速更快
DOC
高出20.0%
-16.9%
净利率更高
DOC
高出69.3%
3.9%
自由现金流更多
DOC
多$351.1M
$5.9M
两年增速更快
DOC
近两年复合增速
-5.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $370.3M |
| 净利润 | $114.0M | $14.5M |
| 毛利率 | — | 70.7% |
| 营业利润率 | 17.4% | 6.3% |
| 净利率 | 73.2% | 3.9% |
| 营收同比 | 3.1% | -16.9% |
| 净利润同比 | 2406.4% | 140.1% |
| 每股收益（稀释后） | $0.16 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCNUS
| Q4 25 | $719.4M | $370.3M | ||
| Q3 25 | $705.9M | $364.2M | ||
| Q2 25 | $694.3M | $386.1M | ||
| Q1 25 | $702.9M | $364.5M | ||
| Q4 24 | $698.0M | $445.6M | ||
| Q3 24 | $700.4M | $430.1M | ||
| Q2 24 | $695.5M | $439.1M | ||
| Q1 24 | $606.6M | $417.3M |
净利润DOCNUS
| Q4 25 | $114.0M | $14.5M | ||
| Q3 25 | $-117.1M | $17.1M | ||
| Q2 25 | $31.7M | $21.1M | ||
| Q1 25 | $42.8M | $107.5M | ||
| Q4 24 | $4.5M | $-36.1M | ||
| Q3 24 | $85.9M | $8.3M | ||
| Q2 24 | $146.0M | $-118.3M | ||
| Q1 24 | $6.7M | $-533.0K |
毛利率DOCNUS
| Q4 25 | — | 70.7% | ||
| Q3 25 | 58.6% | 70.5% | ||
| Q2 25 | 60.2% | 68.8% | ||
| Q1 25 | 61.1% | 67.8% | ||
| Q4 24 | 60.3% | 62.7% | ||
| Q3 24 | 60.0% | 70.1% | ||
| Q2 24 | 60.6% | 70.0% | ||
| Q1 24 | 59.8% | 70.5% |
营业利润率DOCNUS
| Q4 25 | 17.4% | 6.3% | ||
| Q3 25 | 9.2% | 5.9% | ||
| Q2 25 | 5.7% | 8.0% | ||
| Q1 25 | 7.7% | -2.7% | ||
| Q4 24 | -2.2% | -11.9% | ||
| Q3 24 | 14.1% | 4.2% | ||
| Q2 24 | 22.3% | -28.6% | ||
| Q1 24 | 3.7% | 2.1% |
净利率DOCNUS
| Q4 25 | 73.2% | 3.9% | ||
| Q3 25 | -16.6% | 4.7% | ||
| Q2 25 | 4.6% | 5.5% | ||
| Q1 25 | 6.1% | 29.5% | ||
| Q4 24 | 0.7% | -8.1% | ||
| Q3 24 | 12.3% | 1.9% | ||
| Q2 24 | 21.0% | -26.9% | ||
| Q1 24 | 1.1% | -0.1% |
每股收益（稀释后）DOCNUS
| Q4 25 | $0.16 | $0.27 | ||
| Q3 25 | $-0.17 | $0.34 | ||
| Q2 25 | $0.05 | $0.43 | ||
| Q1 25 | $0.06 | $2.14 | ||
| Q4 24 | $0.02 | $-0.73 | ||
| Q3 24 | $0.12 | $0.17 | ||
| Q2 24 | $0.21 | $-2.38 | ||
| Q1 24 | $0.01 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $239.8M |
| 总债务越低越好 | $9.8B | — |
| 股东权益账面价值 | $7.5B | $805.2M |
| 总资产 | $20.3B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.31× | — |
8季度趋势，按日历期对齐
现金及短期投资DOCNUS
| Q4 25 | $467.5M | $239.8M | ||
| Q3 25 | $91.0M | $253.0M | ||
| Q2 25 | $89.4M | $265.4M | ||
| Q1 25 | $70.6M | $213.6M | ||
| Q4 24 | $119.8M | $198.0M | ||
| Q3 24 | $180.4M | $237.8M | ||
| Q2 24 | $106.9M | $232.9M | ||
| Q1 24 | $101.8M | $221.2M |
总债务DOCNUS
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — | ||
| Q1 24 | $8.8B | — |
股东权益DOCNUS
| Q4 25 | $7.5B | $805.2M | ||
| Q3 25 | $7.6B | $799.8M | ||
| Q2 25 | $7.9B | $787.8M | ||
| Q1 25 | $8.2B | $754.0M | ||
| Q4 24 | $8.4B | $651.5M | ||
| Q3 24 | $8.6B | $706.9M | ||
| Q2 24 | $8.8B | $686.2M | ||
| Q1 24 | $8.9B | $810.2M |
总资产DOCNUS
| Q4 25 | $20.3B | $1.4B | ||
| Q3 25 | $19.6B | $1.4B | ||
| Q2 25 | $19.8B | $1.4B | ||
| Q1 25 | $19.8B | $1.4B | ||
| Q4 24 | $19.9B | $1.5B | ||
| Q3 24 | $20.0B | $1.6B | ||
| Q2 24 | $20.2B | $1.6B | ||
| Q1 24 | $20.5B | $1.7B |
负债/权益比DOCNUS
| Q4 25 | 1.31× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 0.99× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $16.6M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $5.9M |
| 自由现金流率自由现金流/营收 | 49.6% | 1.6% |
| 资本支出强度资本支出/营收 | 124.4% | 2.9% |
| 现金转化率经营现金流/净利润 | 10.99× | 1.15× |
| 过去12个月自由现金流最近4个季度 | — | $46.0M |
8季度趋势，按日历期对齐
经营现金流DOCNUS
| Q4 25 | $1.3B | $16.6M | ||
| Q3 25 | $315.0M | $27.5M | ||
| Q2 25 | $363.5M | $35.8M | ||
| Q1 25 | $279.4M | $389.0K | ||
| Q4 24 | $1.1B | $25.8M | ||
| Q3 24 | $318.2M | $31.4M | ||
| Q2 24 | $316.2M | $51.2M | ||
| Q1 24 | $152.6M | $3.3M |
自由现金流DOCNUS
| Q4 25 | $357.0M | $5.9M | ||
| Q3 25 | — | $17.6M | ||
| Q2 25 | — | $35.8M | ||
| Q1 25 | — | $-13.2M | ||
| Q4 24 | $333.7M | $13.2M | ||
| Q3 24 | — | $22.8M | ||
| Q2 24 | — | $43.1M | ||
| Q1 24 | — | $-9.0M |
自由现金流率DOCNUS
| Q4 25 | 49.6% | 1.6% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | -3.6% | ||
| Q4 24 | 47.8% | 3.0% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | — | -2.1% |
资本支出强度DOCNUS
| Q4 25 | 124.4% | 2.9% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | 105.6% | 2.8% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 2.9% |
现金转化率DOCNUS
| Q4 25 | 10.99× | 1.15× | ||
| Q3 25 | — | 1.61× | ||
| Q2 25 | 11.48× | 1.69× | ||
| Q1 25 | 6.52× | 0.00× | ||
| Q4 24 | 235.43× | — | ||
| Q3 24 | 3.71× | 3.79× | ||
| Q2 24 | 2.17× | — | ||
| Q1 24 | 22.85× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
NUS
| Other | $161.9M | 44% |
| Mainland China Segment | $52.0M | 14% |
| Southeast Asia Pacific Segment | $50.5M | 14% |
| Europe And Africa Segment | $41.8M | 11% |
| Hong Kong Taiwan Segment | $29.6M | 8% |
| South Korea Segment | $28.4M | 8% |
| Rhyz Other Segment | $6.1M | 2% |
